177Lu-DOTA Therapy – 150 to 200 mCi

Targeted radionuclide therapy 177Lu-DOTA Therapy – 150 to 200 mCi is an advanced form of targeted radionuclide therapy for selected patients with receptor-positive cancers (such as neuroendocrine tumours). This therapy employs a radioactive molecule known as Lutetium-177 (Lu-177) DOTA-based radiopharmaceutical that is targeted at tumour cells that express specific receptors, thereby delivering radiation specifically to cancer cells.

Dr. Nikunj Jain and our Nuclear Medicine team at Molecular Diagnostics and Therapy ensure that a patient's treatment is planned for optimised imaging, personalised radionuclide therapy and receptor imaging evaluation. Treatment is tailored to the results of the diagnostic imaging tests, the tumour receptors, patients' general health, and the type of treatment they have previously received.

PRRT (peptide receptor radionuclide therapy) is how Lu-177 DOTA therapy benefits the patient. The radioactive molecule is targeted towards cells carrying receptors on the surface of tumour cells, enters the tumour cells, and exposes the tumour cells to targeted radiation, which damages cancer cells but causes minimal radiation to the surrounding healthy cells.

The typical dosage range of 150-200mCi is used, which varies with disease, tumor burden, patient condition, renal function, and treatment protocol determined by the Nuclear Medicine specialist.

What is 177Lu-DOTA Therapy?

177Lu-DOTA Therapy is a targeted molecular therapy consisting of a peptide where a radioactive isotope of Lutetium-177 is attached to a DOTA molecule. This compound has been developed for recognition and binding to a certain receptor, which is found on tumour cells. This treatment helps to address issues such as:

• Targeted destruction of receptor-positive tumour cells.

• Treatment of advanced or metastatic neuroendocrine tumours.

• Reducing tumour progression.

• Controlling symptoms related to hormone-producing tumours.

• Providing a personalised treatment option based on tumour biology.

• Delivering radiation directly to cancer cells while reducing damage to normal tissues.

Before therapy, receptor-based imaging such as 68Ga-DOTATATE PET CT may be performed to confirm receptor expression and evaluate treatment suitability.

Why is the 150 to 200 mCi Dose Used?

A therapeutic activity of 150 to 200 mCi may be recommended depending on:

• Type and stage of tumour.

• Extent of disease spread.

• Tumour receptor expression on PET imaging.

• Previous treatments received.

• Kidney function and bone marrow reserve.

• Overall patient health condition.

This therapeutic range is commonly used in selected patients requiring targeted radiation treatment for receptor-positive malignancies. The final dose and number of therapy cycles are decided by the Nuclear Medicine specialist based on individual patient requirements.

Conditions Where 177Lu-DOTA Therapy May Be Considered

177Lu-DOTA therapy is primarily used for receptor-positive tumours, including:

Neuroendocrine Tumours (NETs)

Helps treat advanced neuroendocrine tumours showing somatostatin receptor expression.

Gastrointestinal Neuroendocrine Tumours

May be used for tumours arising from the digestive system, including small intestine and pancreatic NETs.

Pancreatic Neuroendocrine Tumours

Can help manage selected metastatic or progressive pancreatic neuroendocrine cancers.

Metastatic Receptor-Positive Disease

May be considered when tumour cells demonstrate strong receptor uptake on molecular imaging.

Preparation Before 177Lu-DOTA Therapy

Proper preparation is required before therapy to ensure maximum treatment effectiveness and patient safety.

1. Receptor Imaging Evaluation

Before treatment, patients may undergo:

• 68Ga-DOTATATE PET CT scan.

• Review of previous imaging studies.

• Assessment of tumour receptor expression.

• Evaluation of disease spread.

This helps determine whether the tumour is suitable for PRRT.

2. Blood Tests and Organ Function Assessment

Before therapy, doctors may evaluate:

• Complete blood count (CBC).

• Kidney function tests.

• Liver function tests.

• Serum creatinine levels.

• Other required laboratory investigations.

Kidney function assessment is particularly important because kidneys help remove the radioactive compound from the body.

3. Amino Acid Infusion Preparation

A special amino acid infusion may be given during therapy to protect the kidneys from radiation exposure. The infusion helps reduce radiation absorption by kidney tissues while allowing the therapeutic compound to target tumour cells.

4. Medication Review

Inform your doctor about:

• Current medications.

• Hormonal treatments.

• Supplements.

• Previous chemotherapy or radiotherapy.

• Any allergies or medical conditions.

How is 177Lu-DOTA Therapy (150 to 200 mCi) Administered?

The therapy is administered through an intravenous route under the supervision of the Nuclear Medicine team. Key points include:

• The prescribed Lu-177 DOTA radiopharmaceutical is administered through a vein.

• Amino acid infusion may be started before, during, and after therapy for kidney protection.

• The radioactive compound travels through the bloodstream.

• It attaches to tumour cells expressing specific receptors.

• Radiation is delivered directly to tumour tissues.

• The patient is monitored during and after administration.

The treatment session may require several hours depending on preparation, infusion, and monitoring requirements.

Post-Therapy Safety Instructions

After receiving 177Lu-DOTA therapy, radiation safety precautions are recommended to reduce unnecessary exposure to others. Patients may be advised to:

• Drink adequate fluids to help remove excess radioactivity.

• Follow radiation safety instructions provided by the Nuclear Medicine team.

• Maintain distance from pregnant women and young children for the advised duration.

• Maintain good personal hygiene.

• Wash hands regularly.

• Follow toilet safety precautions.

• Avoid prolonged close contact when instructed.

Specific instructions may vary depending on administered activity and radiation measurements.

Follow-Up After 177Lu-DOTA Therapy

Regular follow-up is important to evaluate treatment response and monitor safety. Follow-up may include:

• Clinical assessment.

• Blood count monitoring.

• Kidney and liver function tests.

• Hormonal marker evaluation if required.

• Follow-up PET CT or other imaging studies.

• Assessment of tumour response.

The number of therapy cycles and follow-up schedule are decided according to treatment response and clinical condition.

Benefits of 177Lu-DOTA Therapy (150 to 200 mCi)

• Targeted treatment for receptor-positive tumours.

• Delivers radiation directly to cancer cells.

• Helps control tumour growth and disease progression.

• Useful in selected advanced neuroendocrine tumours.

• Personalised therapy based on molecular imaging findings.

• May improve quality of life by reducing tumour-related symptoms.

• Minimises radiation exposure to many normal tissues.

Possible Side Effects

Side effects may vary depending on treatment dose, number of cycles, and patient condition. Possible side effects include:

• Fatigue

• Nausea

• Temporary loss of appetite

• Mild abdominal discomfort

• Temporary reduction in blood counts

• Changes in kidney function

• Dry mouth in some patients

• Hormonal changes in selected cases

The Nuclear Medicine team monitors patients carefully to manage and reduce possible treatment-related effects.

Conclusion

Targeted radionuclide therapy – 177Lu-DOTA Therapy – 150 to 200 mCi is a sophisticated therapy with targeted radionuclides that offers a personalised treatment approach for patients with receptor-positive tumours, particularly in the treatment of neuroendocrine malignancies. It has the potential to kill tumour cells specifically by using molecular targetry coupled with radioactive treatment, which reduces exposure to healthy tissues.

Successful therapy requires evaluation of receptor imaging, assessment of organ function, and experienced treatment planning. Dr. Nikunj Jain, Molecular Diagnostics and Therapy, offers a complete assessment and tailored recommendations for the entire course of Lu-177 DOTA therapy.

Instructions

• Carry previous medical records, biopsy reports, PET CT reports, MRI/CT reports, and treatment history.

• Bring recent blood test reports including kidney function and blood counts.

• Inform your doctor about all medications, supplements, and previous therapies.

• Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.

• Follow all preparation instructions provided by the Nuclear Medicine team.

• Maintain adequate hydration before and after therapy as advised.

• Follow radiation safety precautions after treatment.

• Arrive at the centre before the scheduled appointment time for registration and preparation.

• Scan is done after 48 hours of intake of medicine.

निर्देश

• अपनी सभी पुरानी मेडिकल रिपोर्ट जैसे बायोप्सी रिपोर्ट, PET CT रिपोर्ट, MRI/CT रिपोर्ट और इलाज का इतिहास साथ लेकर आएं।

• किडनी फंक्शन और ब्लड काउंट सहित हाल की जांच रिपोर्ट साथ लाएँ।

• डॉक्टर को अपनी सभी दवाइयों, सप्लीमेंट्स और पहले किए गए उपचारों की जानकारी दें।

• यदि आप गर्भवती हैं, गर्भधारण की योजना बना रही हैं या स्तनपान करा रही हैं, तो डॉक्टर को अवश्य बताएं।

• न्यूक्लियर मेडिसिन टीम द्वारा दिए गए सभी निर्देशों का पालन करें।

• उपचार से पहले और बाद में डॉक्टर की सलाह के अनुसार पर्याप्त पानी पिएं।

• उपचार के बाद रेडिएशन सुरक्षा निर्देशों का पालन करें।

• पंजीकरण और तैयारी के लिए निर्धारित समय से पहले केंद्र पर पहुंचें।

Procedure

• Before 177Lu-DOTA Therapy, the Nuclear Medicine team reviews the patient's medical history, receptor imaging findings, laboratory reports, and treatment suitability.

• The prescribed Lutetium-177 DOTA radiopharmaceutical (150–200 mCi) is administered intravenously under specialist supervision.

• Amino acid infusion may be provided during therapy to protect the kidneys from radiation exposure.

• The radioactive compound circulates through the bloodstream and binds to receptor-positive tumour cells.

• Targeted radiation is delivered to tumour tissues, helping damage and destroy cancer cells.

• After therapy, patients receive personalised radiation safety instructions regarding hydration, hygiene, family contact, and precautions.

• Follow-up blood tests and imaging studies are performed as advised to monitor treatment response and overall health.